Skip to content 
Search

Latest Stories

Cipla chief offers clarity on Remdesivir supplies

By Amit Roy

ONE of the best informed on drugs for coronavirus is Yusuf Hamied, chairman of the Indian pharma giant Cipla, who expresses concern that the numbers in­fected in India are “going up and up”.


He says: “It has not yet peaked. Probably the peak will come in August, September.”

And his prognosis?

“I’m only hearing from sources in Amer­ica,” he replies. “Two months ago, it was suggested that up to two million Indians could die.”

Does he think that is a realistic assessment?

“No,” says Hamied, “because what no­body realised then is that although Indians are getting corona, the death rate is rela­tively low because of inbuilt immunity from earlier vaccinations.”

In a country of 1.3 billion, the official figures are that 723,185 people have had the virus. The death toll stands at 20,198, while 441,112 infected have recovered.

Hamied, who is currently at his London home, has disputed a story in the Guardian on June 30, headlined, “US secures world stock of key Covid-19 drug Remdesivir.”

It has caused widespread concern that if and when a vaccine becomes available, the US will again hoover up the world’s supply and leave nothing for others.

The report said: “No other country will be able to buy Remdesivir, which can help recovery from Covid-19, for the next three months at least.

“The US has bought up virtually all the stocks for the next three months of one of the two drugs proven to work against Covid-19, leaving none for the UK, Europe or most of the rest of the world.

“Experts and campaigners are alarmed both by the US uni­lateral action on Remdesivir and the wider implications, for in­stance in the event of a vaccine becoming available.

“The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.”

Hamied confirms that his company Cipla has been giv­en clear­ance to manufacture Remdesivir in India. He tells Eastern Eye: “I will tell you where the [Guardian] story was wrong. The drug Remdesivir was invented by Gilead, an American company. It was intended for use at the time of the Ebola epidemic in Africa, and there it didn’t do very well.

“When corona started, they tried it in America. It’s an antiviral drug. They say it was quite successful. So it has become the drug of choice because there is no com­plete remedy to corona. It is given by intra­venous injections. It’s like one of the many anti-viral drugs that we use in diseases such as HIV AIDs.”

He says of the 20-year patent on Remde­sivir, “invented 16 or 17 years ago, there are three years left (before the patent runs out)”.

Explaining the background of the engagement between Gilead and India, Hamied reveals: “Gilead about 10 years ago gave a number of Indian companies the right to produce some of their drugs in India, still under patent for HIV, called Tenofovir.

“Before expiry of the patent they gave us what they call a ‘voluntary licence’. That means you can go ahead and manufacture the drug. But you’re restricted to the coun­tries where you can sell the drug.”

Hamied goes on: “Then came hepatitis C. They developed the drug Sovaldi and again came to India and gave 10 Indian companies a voluntary licence for Sofosbu­vir and the freedom to market the drug at any price with a small royalty to Gilead.”

He tells the story of Remdesivir: “Again, they have come to India and given Indian companies the right to manufacture and market Remdesivir. They have given us a list of 130 countries where we are allowed to sell.”

He stresses: “It is totally free while the pandemic is on. The minute the pandemic ends they will want to re­negotiate the agreement. So they have been very fair, actually.”

This licence was given a few weeks ago. “They’ve given this to six compa­nies – Cipla, Hetero, Mylan, Cadila, Dr Reddy and Jubilant. We were an­ticipating this. So we did all the homework on Remdesivir.”

The Indian government has cleared two companies to make the drug for “emer­gency use” in India, one being Cipla. “We are manufacturing it in our Goa factory.”

Depending on demand, he reveals that his company could manufacture 30,000 in­jections a week and build up stocks, cur­rently at 400,000 injections, to between one and two million.

Hamied says: “The price in America today for a course of six injections is $2,500 (£1,990). And, in India, the average price is around $65 (£52) per injection. It’s in the market.”

Returning to the Guardian story, Hamied explains: “What the American government can do is only ask Gilead, ‘You first supply us.’ They can block export from America. But they can’t stop Cipla and other licensed companies from making it and supplying it wherever they wish. Our product, Cipremi, is not approved in America. We can only take an approved product there if it is US FDA approved.”

As to how good the drug is at helping coronavirus patients, Hamied emphasises: “It doesn’t cure but can give relief. If you don’t take the drug, you may be in hospital for 11 days. And if you take the drug, you’re in hospital eight days.”

He reveals the news from India is not that encouraging because doctors have found it has side effects, leading, for example, to liver problems. “So, instead of giving it for six days, they may reduce that to five.”

Hamied mentions two other drugs being used for coronavirus patients. “There is a drug of Roche which is under patent. The drug is called Actemra – the generic name is Tocilizuma. Cipla is the distributor of the drug. We don’t make it.

“There is a drug called Favipiravir. And this is an antiviral drug, a Japanese drug off patent. And the Japanese and the Chinese and the Russians have claimed that it is very good for corona. One company called Glenmark has got approval in India. Cipla is also making it and likely to get approval any day.”

Finally, on the search for a vaccine for the virus, Hamied says: “Our friends, the Poonawallas, who own the Serum Institute of India, are very optimistic and will be among the leaders to bring out a suitable vaccine for Covid-19.”

More For You

Fauja Singh
Singh did not possess a birth certificate, but his family said he was born on April 1, 1911. (Photo: Getty Images)
Getty images

Accused in Fauja Singh death case arrested, sent to judicial custody

A CANADA-based man accused of fatally hitting 114-year-old marathoner Fauja Singh with an SUV in Punjab has been arrested and sent to judicial custody. Officials said the accused had returned to India just three weeks ago.

Jalandhar rural senior superintendent of police (SSP) Harvinder Singh told a press conference that 26-year-old Amritpal Singh Dhillon was arrested on Tuesday night and his vehicle was seized. He said police treated the case as a challenge and solved it within 30 hours.

Keep ReadingShow less
Indian Americans

A new survey shows growing cultural and emotional ties to India among US-born Indian Americans.

Getty Images

US-born Indian Americans show stronger ties to heritage: Survey

A NEW report has shown that Indian Americans born in the United States are displaying stronger identification with their Indian heritage than in previous years.

The 2024 Indian American Attitudes Survey by the Carnegie Endowment for International Peace, conducted online with 1,206 respondents, found that 86 per cent of US-born Indian Americans said that being Indian is “very” or “somewhat” important to them. This marks an increase from 70 per cent in 2020. The share who considered their Indian identity as “not too important” or “not important at all” dropped from 30 to 15 per cent.

Keep ReadingShow less
UK India call centre scam

The criminals used sophisticated tactics to disguise their identity

iStock

UK and India team up to bust call centre scam

THE National Crime Agency (NCA) has revealed details of a “groundbreaking collaboration” with India’s Central Bureau of Investigation (CBI) and American teams to bust a fraud call centre scam operating from Noida in north India that targeted British victims.

The international investigation began early last year after NCA officers in the US received information from Microsoft, which was compared with City of London Police’s Action Fraud Reports. The NCA and FBI Attaché in Delhi shared intelligence with the CBI, leading to “urgent action” and the arrest of two people.

Keep ReadingShow less
Sir Anwar’s 90th birthday crowns
Bestway Group’s golden jubilee

Lord David Cameron presenting shield to Sir Anwar Pervez with Bestway Group Board Members

Bestway

Sir Anwar’s 90th birthday crowns Bestway Group’s golden jubilee

FORMER prime minister Lord David Cameron led an emotional and heartfelt tribute to Sir Anwar Pervez at a glittering event at the Royal Albert Hall, marking the business titan’s 90th birthday alongside the 50th anniversary of the Bestway Group.

The grand celebration brought together around 800 guests, including senior politicians, diplomats and leading figures from the grocery, pharmacy and finance sectors – industries where Bestway holds a dominant presence – to honour the extraordinary life and achievements of the self-made entrepreneur whose journey from rural Pakistan to British business royalty has inspired generations.

Keep ReadingShow less
Government considers 'handing Post Office to postmasters'

A post office sign hangs above a shop in Belgravia, in London. REUTERS/Hollie Adams

Government considers 'handing Post Office to postmasters'

THE government is exploring whether to transfer control of the Post Office to the people who run its branches, according to a new consultation launched this week.

Minister Gareth Thomas said the move would create "a fresh vision" for the service while rebuilding trust following the Horizon scandal that devastated hundreds of sub-postmasters' lives, reported the BBC.

Keep ReadingShow less